These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 8558457)

  • 1. Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats.
    Rodríguez de Fonseca F; Rubio P; Menzaghi F; Merlo-Pich E; Rivier J; Koob GF; Navarro M
    J Pharmacol Exp Ther; 1996 Jan; 276(1):56-64. PubMed ID: 8558457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a novel and potent corticotropin-releasing factor antagonist in rats.
    Menzaghi F; Howard RL; Heinrichs SC; Vale W; Rivier J; Koob GF
    J Pharmacol Exp Ther; 1994 May; 269(2):564-72. PubMed ID: 8182523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological comparison of two corticotropin-releasing factor antagonists: in vivo and in vitro studies.
    Curtis AL; Grigoriadis DE; Page ME; Rivier J; Valentino RJ
    J Pharmacol Exp Ther; 1994 Jan; 268(1):359-65. PubMed ID: 8301577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corticotropin-releasing factor antagonist attenuates the "anxiogenic-like" effect in the defensive burying paradigm but not in the elevated plus-maze following chronic cocaine in rats.
    Basso AM; Spina M; Rivier J; Vale W; Koob GF
    Psychopharmacology (Berl); 1999 Jul; 145(1):21-30. PubMed ID: 10445369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The involvement of central noradrenergic systems and corticotropin-releasing factor in defensive-withdrawal behavior in rats.
    Yang XM; Gorman AL; Dunn AJ
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1064-70. PubMed ID: 2262892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal.
    Rodríguez de Fonseca F; Carrera MR; Navarro M; Koob GF; Weiss F
    Science; 1997 Jun; 276(5321):2050-4. PubMed ID: 9197270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist.
    Heinrichs SC; De Souza EB; Schulteis G; Lapsansky JL; Grigoriadis DE
    Neuropsychopharmacology; 2002 Aug; 27(2):194-202. PubMed ID: 12093593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonism of cannabinoid 1 receptors reverses the anxiety-like behavior induced by central injections of corticotropin-releasing factor and cocaine withdrawal.
    Kupferschmidt DA; Newman AE; Boonstra R; Erb S
    Neuroscience; 2012 Mar; 204():125-33. PubMed ID: 21784132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased ethanol self-administration and anxiety-like behavior during acute ethanol withdrawal and protracted abstinence: regulation by corticotropin-releasing factor.
    Valdez GR; Roberts AJ; Chan K; Davis H; Brennan M; Zorrilla EP; Koob GF
    Alcohol Clin Exp Res; 2002 Oct; 26(10):1494-501. PubMed ID: 12394282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonism of CRF(2) receptors produces anxiolytic behavior in animal models of anxiety.
    Takahashi LK; Ho SP; Livanov V; Graciani N; Arneric SP
    Brain Res; 2001 Jun; 902(2):135-42. PubMed ID: 11384606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-stress action of a corticotropin-releasing factor antagonist on behavioral reactivity to stressors of varying type and intensity.
    Heinrichs SC; Menzaghi F; Pich EM; Baldwin HA; Rassnick S; Britton KT; Koob GF
    Neuropsychopharmacology; 1994 Nov; 11(3):179-86. PubMed ID: 7865099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CRF(1) receptor antagonist DMP696 produces anxiolytic effects and inhibits the stress-induced hypothalamic-pituitary-adrenal axis activation without sedation or ataxia in rats.
    McElroy JF; Ward KA; Zeller KL; Jones KW; Gilligan PJ; He L; Lelas S
    Psychopharmacology (Berl); 2002 Dec; 165(1):86-92. PubMed ID: 12474122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of corticotropin-releasing factor antagonist on behavioral and neuroendocrine responses during exposure to defensive burying paradigm in rats.
    Korte SM; Korte-Bouws GA; Bohus B; Koob GF
    Physiol Behav; 1994 Jul; 56(1):115-20. PubMed ID: 8084889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of chronic treatment with either dopamine D1 or D2 receptor agonists on the acute neuroendocrine actions of the highly potent synthetic cannabinoid HU-210 in male rats.
    Rodríguez de Fonseca FR; Villanúa MA; Muñoz RM; San-Martin-Clark O; Navarro M
    Neuroendocrinology; 1995 Jun; 61(6):714-21. PubMed ID: 7659195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corticotropin-releasing hormone (CRH) mRNA expression in rat central amygdala in cannabinoid tolerance and withdrawal: evidence for an allostatic shift?
    Caberlotto L; Rimondini R; Hansson A; Eriksson S; Heilig M
    Neuropsychopharmacology; 2004 Jan; 29(1):15-22. PubMed ID: 12968131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a benzodiazepine receptor agonist and corticotropin-releasing hormone receptor antagonists on long-term foot-shock-induced increase in defensive withdrawal behavior.
    Bruijnzeel AW; Stam R; Wiegant VM
    Psychopharmacology (Berl); 2001 Nov; 158(2):132-9. PubMed ID: 11702086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Astressin, a corticotropin releasing factor antagonist, reverses the anxiogenic effects of urocortin when administered into the basolateral amygdala.
    Sajdyk TJ; Gehlert DR
    Brain Res; 2000 Sep; 877(2):226-34. PubMed ID: 10986336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral corticotropin-releasing factor mediates the elevation of plasma IL-6 by immobilization stress in rats.
    Ando T; Rivier J; Yanaihara H; Arimura A
    Am J Physiol; 1998 Nov; 275(5):R1461-7. PubMed ID: 9791062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks peripheral CRF- and abdominal surgery-induced delayed gastric emptying in rats.
    Martínez V; Rivier J; Taché Y
    J Pharmacol Exp Ther; 1999 Aug; 290(2):629-34. PubMed ID: 10411571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subtype-selective corticotropin-releasing factor receptor agonists exert contrasting, but not opposite, effects on anxiety-related behavior in rats.
    Zhao Y; Valdez GR; Fekete EM; Rivier JE; Vale WW; Rice KC; Weiss F; Zorrilla EP
    J Pharmacol Exp Ther; 2007 Dec; 323(3):846-54. PubMed ID: 17855476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.